Gregg Alton

Gregg Huber Alton currently works at Novavax, Inc., as Independent Director from 2020, Corcept Therapeutics, Inc., as Independent Director from 2020, Boys & Girls Club of Oakland, as Director from 2011, Gilead Foundation, as Director, The Aids Institute, Inc., as Director from 2013, The Black Women's Health Imperative, as Director from 2020, Brii Biosciences Ltd. (China), as Independent Non-Executive Director from 2021, Hepatitis Fund, as Director, Education Training & Research Associates, Inc., as Director from 2021, Global Antibiotic Research & Development Partnership, as Director from 2021, and Partners In Health, as Trustee-Emeritus from 2014.
Mr. Alton also formerly worked at Sonoma Pharmaceuticals, Inc., as Independent Director from 2011 to 2013, Celladon Corp., as Director in 2013, Pharmaceutical Research & Manufacturers of America, as Director, The Bay Area Bioscience Association, as Director, Collidion, Inc. (California), as Director, Lunai Bioworks, Inc., as Lead Independent Director from 2022 to 2024, Gilead Sciences, Inc., as Chief Patient Officer in 2019, AIDS Healthcare Foundation, as Treasurer, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC, as Associate Attorney, and Cooley Godward LLP, as Attorney from 1998 to 1999.
Mr. Alton received his graduate degree from Stanford University and graduate degree in 1989 from the University of California, Berkeley.